CluenexAgilent Technologies A
Agilent Technologies scores good on business quality (6.0 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Agilent Technologies does
Agilent Technologies provides analytical instruments, software, and consumables to life sciences, diagnostics, and applied chemical markets, generating revenue primarily from recurring lab services and equipment sales to pharmaceutical and research customers. The business focuses on maintaining high dividend stability while navigating sluggish top-line momentum across its core laboratory segments.
- What it does best
Agilent excels in operating margin delivery, posting an operating margin of 22.2% that outpaces peers like Waters at 11.2% and IQVIA at 13.9%, supported by entrenched customer workflows in analytical laboratories.
- The main risk
Sluggish revenue growth poses a persistent risk, with an annual growth rate of 6.7% lagging behind broader market opportunities and leaving the firm vulnerable to spending cuts in pharmaceutical R&D budgets.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at 22.2% with a free cash flow margin of 17.2%, reflecting stable operational efficiency. The business scales profitably as revenue increases, though growth rates remain constrained.
The moat relies on high switching costs locking in enterprise laboratory customers through proprietary software and consumables. Operating margin ranks in the top quartile at the 70th sector percentile.
Revenue growth registers at 6.7%, placing the company squarely in the middle of the pack at the 42nd sector percentile and demonstrating a slow recovery compared to its uneven historical annual summary.
Debt-to-equity sits at 0.5 with interest coverage at 15.5x, meaning debt servicing costs are well-covered. Free cash flow reached $1.3B, showing a softer trend compared to historical peaks. Getting softer.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $96K outside pre-planned sales.
Our sealed record on A
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Agilent Technologies scores good on the Cluenex quality check (6.0 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health strong.
In the last 90 days of SEC Form 4 filings: 1 sold $96K outside pre-planned sales.
Nov 23, 2026, after the close.
See A today
- Today's verdict on A, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Agilent Technologies (A)”, https://cluenex.com/stocks/a/, data as of Oct 10, 2026.